Clinical Trial Update: Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery [Phase 4]

View source ↗

Summary

Phase 4 clinical investigation of the Dextenza 0.4 mg intracanalicular insert for cataract surgery has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract

Drugs mentioned

• Dextenza (Dexamethasone)

Snippet

Sponsor: Cathleen McCabe MD | Conditions: Cataract | Phase 4 | Status: TERMINATED